Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

You may be eligible if

• Confirmed cases of SARS-CoV-2 infection hospitalized in reference services identified by the Ministry of Health and Social Action of Senegal
• Adults (≥18 years)
• Full understanding and consent to participate to the trial
• No contraindications to taking the tested treatments
• Clinical status from 3 to 5 on the seven-category ordinal scale
• Pneumonia highlighted by infiltration of the lungs by chest CT scan or chest radiography
• Absence of contraindications to radiographic examinations (X-ray and/or CT scan) for diagnosis and/or follow-up
• Inclusion in the 72 hours following the radiological pneumonia confirmation
• Pregnant or breastfeeding woman
• Patient at high risk of death within 3 days of inclusion, in the clinician's opinion
• Corrected QT interval (QTc) \>500ms
• Heart electrical dysfunction: atrioventricular block Mobitz type II second-degree, high-grade or complete without a functioning pacemaker
• Uncontrolled and clinically significant heart diseases, such as arrhythmia, angina or decompensated congestive heart failure
• Kidney failure (Cl \< 30 mL/min)
• Patients with liver cirrhosis whose Child-Puch score is B or C
• Patients who have liver disease abnormalities with ALT or AST \> 5 times ULN
• Patients who have a known HIV status
• Patients who have other clinically-important diseases in decompensation which may interfere with the evaluation or completion of the tested treatment's procedure, in the clinician's opinion
• Patients with a clinical or psychological condition which, in the clinician's opinion, does not allow adequate evaluation of the tested treatment
• Known allergy to the studied treatment regimen
• Other contraindications with the studied treatment regimen
• Known drug-drug interaction with a treatment usually taken by the participant contraindicating one of the studied treatment regimen